RT Journal Article
T1 Hydroxytyrosol Supplementation Modifies Plasma Levels of Tissue Inhibitor of Metallopeptidase 1 in Women with Breast Cancer.
A1 Ramirez-Tortosa, Cesar
A1 Sanchez, Ana
A1 Perez-Ramirez, Cristina
A1 Quiles, Jose Luis
A1 Robles-Almazan, María
A1 Pulido-Moran, Mario
A1 Sanchez-Rovira, Pedro
A1 Ramirez-Tortosa, MCarmen
K1 MMP-9
K1 TIMP-1
K1 antioxidant
K1 extra virgin olive oil
K1 hydroxytyrosol
AB The etiology of breast cancer can be very different. Most antineoplastic drugs are not selective against tumor cells and also affect normal cells, leading to a wide variety of adverse reactions such as the production of free radicals by altering the redox state of the organisms. Therefore, the objective of this study was to elucidate if hydroxytyrosol (HT) (an antioxidant present in extra virgin olive oil) has a chemomodulatory effect when combined with the chemotherapeutic drugs epirubicin and cyclophosphamide followed by taxanes in breast cancer patients. Changes in plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) throughout the chemotherapy treatment were studied. Both molecules are involved in cell proliferation, apoptosis, neoangiogenesis, and metastasis in breast cancer patients. Women with breast cancer were divided into two groups: a group of patients receiving a dietary supplement of HT and a control group of patients receiving placebo. The results showed that the plasma levels of TIMP-1 in the group of patients receiving HT were significantly lower than those levels found in the control group after the epirubicin-cyclophosphamide chemotherapy.
SN 2076-3921
YR 2019
FD 2019-09-11
LK https://hdl.handle.net/10668/26794
UL https://hdl.handle.net/10668/26794
LA en
DS RISalud
RD Apr 20, 2025